GILEAD SCIENCES, INC. Amortization of Intangible Assets
GILEAD SCIENCES, INC. (GILD) reported Amortization of Intangible Assets of $2.40 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-02-24
- GILEAD SCIENCES, INC. amortization of intangible assets for the quarter ending 2023-12-31 was $600.00M, a 20.00% increase year-over-year.
- GILEAD SCIENCES, INC. amortization of intangible assets for the quarter ending 2023-09-30 was $598.00M, a 34.38% increase year-over-year.
- GILEAD SCIENCES, INC. amortization of intangible assets for the quarter ending 2023-06-30 was $598.00M, a 34.38% increase year-over-year.
- GILEAD SCIENCES, INC. amortization of intangible assets for the quarter ending 2023-03-31 was $546.00M, a 22.70% increase year-over-year.
- GILEAD SCIENCES, INC. amortization of intangible assets for fiscal 2025 was $2.40B, a 0.00% change from fiscal 2024.
- GILEAD SCIENCES, INC. amortization of intangible assets for fiscal 2024 was $2.40B, a 4.35% increase from fiscal 2023.
- GILEAD SCIENCES, INC. amortization of intangible assets for fiscal 2023 was $2.30B, a 27.78% increase from fiscal 2022.
- GILEAD SCIENCES, INC. amortization of intangible assets for fiscal 2022 was $1.80B, a 5.88% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.40B 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $2.40B 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $600.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.20B derived: sum of 2 quarters · filed 2026-02-24 | $1.80B derived: sum of 3 quarters · filed 2026-02-24 | $2.30B 10-K · filed 2026-02-24 |
| 2023-09-30 | $598.00M 10-Q · filed 2023-11-07 | $1.20B derived: sum of 2 quarters · filed 2023-11-07 | $1.70B 10-Q · filed 2023-11-07 | $2.24B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $598.00M 10-Q · filed 2023-08-04 | $1.10B 10-Q · filed 2023-08-04 | $1.64B derived: sum of 3 quarters · filed 2025-02-28 | $2.09B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $546.00M 10-Q · filed 2023-05-03 | $1.05B derived: sum of 2 quarters · filed 2025-02-28 | $1.49B derived: sum of 3 quarters · filed 2025-02-28 | $1.94B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $500.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $945.00M derived: sum of 2 quarters · filed 2025-02-28 | $1.39B derived: sum of 3 quarters · filed 2025-02-28 | $1.80B 10-K · filed 2025-02-28 |
| 2022-09-30 | $445.00M 10-Q · filed 2023-11-07 | $890.00M derived: sum of 2 quarters · filed 2023-11-07 | $1.30B 10-Q · filed 2023-11-07 | $1.74B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $445.00M 10-Q · filed 2023-08-04 | $890.00M 10-Q · filed 2023-08-04 | $1.29B derived: sum of 3 quarters · filed 2024-02-23 | $1.73B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $445.00M 10-Q · filed 2023-05-03 | $845.00M derived: sum of 2 quarters · filed 2024-02-23 | $1.29B derived: sum of 3 quarters · filed 2024-02-23 | $1.73B derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $400.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $841.00M derived: sum of 2 quarters · filed 2024-02-23 | $1.28B derived: sum of 3 quarters · filed 2024-02-23 | $1.70B 10-K · filed 2024-02-23 |
| 2021-09-30 | $441.00M 10-Q · filed 2022-11-02 | $881.00M derived: sum of 2 quarters · filed 2022-11-02 | $1.30B 10-Q · filed 2022-11-02 | $1.63B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $440.00M 10-Q · filed 2022-08-08 | $835.00M 10-Q · filed 2022-08-08 | $1.19B derived: sum of 3 quarters · filed 2023-02-22 | $1.47B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $395.00M 10-Q · filed 2022-05-04 | $751.00M derived: sum of 2 quarters · filed 2023-02-22 | $1.03B derived: sum of 3 quarters · filed 2023-02-22 | $1.31B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $356.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $637.00M derived: sum of 2 quarters · filed 2023-02-22 | $919.00M derived: sum of 3 quarters · filed 2023-02-22 | $1.20B 10-K · filed 2023-02-22 |
| 2020-09-30 | $281.00M 10-Q · filed 2021-11-03 | $563.00M derived: sum of 2 quarters · filed 2021-11-03 | $844.00M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $282.00M 10-Q · filed 2021-08-05 | $563.00M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $281.00M 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | $281.00M 10-Q · filed 2020-11-04 | $569.00M derived: sum of 2 quarters · filed 2020-11-04 | $868.00M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $288.00M 10-Q · filed 2020-08-06 | $587.00M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $299.00M 10-Q · filed 2020-05-06 | |||
| 2018-09-30 | $301.00M 10-Q · filed 2019-11-05 | $601.00M derived: sum of 2 quarters · filed 2019-11-05 | $902.00M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $300.00M 10-Q · filed 2019-08-06 | $601.00M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $301.00M 10-Q · filed 2019-05-08 | |||
| 2013-06-30 | $21.50M 10-Q · filed 2013-08-01 | $43.10M 10-Q · filed 2013-08-01 | $58.80M derived: sum of 3 quarters · filed 2014-02-25 | $74.60M derived: sum of 4 quarters · filed 2014-02-25 |
| 2013-03-31 | $21.50M 10-Q · filed 2013-05-08 | $37.30M derived: sum of 2 quarters · filed 2014-02-25 | $53.10M derived: sum of 3 quarters · filed 2014-02-25 | $68.90M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-12-31 | $15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $31.60M derived: sum of 2 quarters · filed 2014-02-25 | $47.40M derived: sum of 3 quarters · filed 2014-02-25 | $63.30M 10-K · filed 2014-02-25 |
| 2012-09-30 | $15.80M 10-Q · filed 2012-11-06 | $31.60M derived: sum of 2 quarters · filed 2013-08-01 | $47.50M 10-Q · filed 2012-11-06 | $64.80M derived: sum of 4 quarters · filed 2013-08-01 |
| 2012-06-30 | $15.80M 10-Q · filed 2013-08-01 | $31.70M 10-Q · filed 2013-08-01 | $49.00M derived: sum of 3 quarters · filed 2013-08-01 | $66.40M derived: sum of 4 quarters · filed 2013-08-01 |
| 2012-03-31 | $15.80M 10-Q · filed 2013-05-08 | $33.20M derived: sum of 2 quarters · filed 2013-05-08 | $50.60M derived: sum of 3 quarters · filed 2013-05-08 | $68.00M derived: sum of 4 quarters · filed 2013-05-08 |
| 2011-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $34.80M derived: sum of 2 quarters · filed 2013-02-27 | $52.20M derived: sum of 3 quarters · filed 2013-02-27 | $69.60M 10-K · filed 2013-02-27 |
| 2011-09-30 | $17.40M 10-Q · filed 2012-11-06 | $34.80M derived: sum of 2 quarters · filed 2012-11-06 | $52.20M 10-Q · filed 2012-11-06 | |
| 2011-06-30 | $17.40M 10-Q · filed 2012-08-01 | $34.80M 10-Q · filed 2012-08-01 | ||
| 2010-12-31 | $59.90M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |